2 completed, 1 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Active not recruiting 1 |
Follow Advanced Accelerator Applications: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution - Gastro-enteropancreatic Neuroendocrine Tumor | Phase 3 | Active not recruiting | Advanced Accelerator Applications | 226 | 2020-01-08 | 2026-01-21 |
| A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Octreotide LAR, 177Lu-DOTA0-Tyr3-Octreotate - Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour | Phase 3 | Completed | Advanced Accelerator Applications | 231 | 2012-09-06 | 2022-04-04 |
| Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head Comparison Rubidium-82, Sestamibi. reconstitution with sodium pertechnetate (99mTc) - Coronary Artery Disease | Phase 3 | Completed | Advanced Accelerator Applications | 135 | 2011-02-01 | 2014-05-14 |
Coronary Artery Disease (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Neuroendocrine Tumors (1)
Octreotide (2) · lutetium Lu 177 dotatate (2) · Receptor-Like Protein Tyrosine Phosphatases, Class 2 (1) · Rubidium-82 (1) · Sodium Pertechnetate Tc 99m (1) · pasireotide (1)
United Kingdom (3) · France (2) · Germany (2) · Italy (2) · Spain (2) · United States (2) · Belgium (1) · Canada (1) · Netherlands (1) · Portugal (1) · South Korea (1)
PMID 28076709, PMID 29878866, PMID 32123969, PMID 33973550, PMID 34793718, PMID 38851203, PMID 39570708, PMID 40473457, PMID 42604001
2009 (1), 2023 (1)